• Skip to main content
  • Skip to secondary menu
  • Skip to footer
Clinical Digital Resource Collaborative

Clinical Digital Resource Collaborative

Designed and developed in the North East and North Cumbria by local GPs

National Health Service
  • Home
  • About Us
  • The Team
  • Resources
    • Referral Forms
    • EMIS Resources
      • CDRC EMIS Access
      • Long Term Condition (LTC) Management
      • Impact and Investment Fund (IIF)
      • Medicine Management
        • Precision Monitoring
        • DMARDs and High Risk Drugs
        • Safe Prescribing of Opioids / Opiates
      • Specialties
        • Cancer Guide for EMIS
        • EMIS Cardiovascular Overview
          • Atrial Fibrillation Guide for EMIS
          • CDRC Precision CVD Prevention Template
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Guide for EMIS
          • Peripheral Arterial Disease EMIS Guide
        • Infection
          • Infections Guide for EMIS
          • Blood Borne Virus (BBV)
        • Neurology Guide for EMIS
        • Respiratory Overview
          • BeatAsthma+
    • SystmOne Resources
      • National Early Warning Score 2 (NEWS2) Guide for SystmOne
      • Getting Started
        • Getting Started – Access
        • Getting Started – How-To’s
      • SystmOne Administration
      • Contract Management
        • Impact and Investment Fund (IIF)
        • Vaccinations
      • Long Term Condition Management
        • Call/ Recall System
        • Recall Recovery System
        • Care Planning
      • Safeguarding System
        • Safeguarding Adults
        • Safeguarding At Risk of Harming Others
        • Safeguarding Family/Household Cause for Concern
        • Safeguarding Children
      • Medicine Management
        • Drugs Requiring Monitoring System
        • Safety & Reviews
        • Safe Prescribing of Opioids / Opiates
        • Safe Prescribing of NSAIDS
        • Safe Prescribing of Lithium
        • Safe Prescribing of Valproate
        • Safe Prescribing of Corticosteroids / Steroids
      • Specialties
        • Blood Borne Virus (BBV) Test Alert for SystmOne
        • BeatAsthma+ Guide for SystmOne
        • Cancer Overview
          • Cancer
          • Suspected Cancer
        • Cardiovascular Overview
          • Cardiology Results
          • Hypertension & Blood Pressure
          • Atrial Fibrillation (AF)
          • Integrated CVD Prevention
          • Peripheral Arterial Disease (PAD)
        • SystmOne Diabetes Overview
          • SystmOne Diabetes Management
          • SystmOne Diabetes Prevention
          • SystmOne Diabetic Kidney Disease
        • ENT Infections
        • Geriatrics Overview
          • Care for Frail Patients
          • Comprehensive Geriatric Assessment
          • Co-ordinated Care
        • Haematology
        • Infection Overview
        • Learning Disabilities
        • Lifestyle
        • Lipids, Familial Hypercholesterolaemia, PCSK9i & Inclisiran Overview
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Search Guide for SystmOne
          • Lipids Protocols
          • Lipids Opt-In Resources
          • Lipid Details and Lipid Lowering Templates
          • Lipid Lowering Template
          • Lipid QoF Support
          • Screening for Familial Hypercholesterolaemia
          • Aetiology of Abnormal Lipids
          • Lipids Strategy
          • Lipids – Recommended Batch Searches
        • MSK Referral Management
        • Neurology
        • Obesity Resources
        • Ophthalmology
        • Palliative Care
        • SystmOne Renal/Urology Overview
          • Chronic Kidney Disease (CKD)
        • Respiratory Overview
          • Asthma Resources
          • Respiratory Infections
        • Rheumatology Overview
          • Bone Health
      • Women’s Health Overview
        • Gynaecology Resource Overview
          • Cervical Screening
          • Contraception
          • Prolapse
      • Vaccination Overview
        • COVID-19 Resources- SystmOne
        • Influenza Vaccination
        • Meningitis B Vaccination
        • Meningitis ACWY Vaccination
        • Pneumococcal Vaccination
        • Shingles Vaccination
  • FAQs
  • News and Events
    • Demonstrations
    • Events
      • Recordings
    • Articles
    • Conference abstracts
  • Contact us
You are here: Home / Resources / SystmOne Resource Centre / SystmOne Specialties / Respiratory Overview / Asthma Resources

Asthma Resources

The following resources are available to support with Asthma management.

Accessing CDRC resources on SystmOne

To access the below resources you will need to be a member of the DCS group on SystmOne. To do this, please follow the instructions on the CDRC SystmOne Access webpage.

Reports

Asthma Reports

A series of reports are available to help improve asthma care and identify high risk patients.  

These reports are in the folder CDRC Quality > Respiratory

They are also described in a Reports tab on the Asthma CDRC template. 

Machine generated alternative text:
? Asthma 3 0 Exacerbation without follow-u 
? Asthma -12 SABA in the last 12m 
? Asthma -6 SABA in the last 12m 
? Asthma 7-11 SABA in the last 12m 
? Asthma 31 LABA on repeat and no ICS # 
review 
? Asthma 3Ga Likely Severe Asthma (high dose ICS, or LAMA or aminophylline or biologics) 
? Asthma 3Gb Likely Moderately Severe Asthma # 
? Asthma 34 - -1 Exacerbation in last 12m 
? Asthma 3 5 Admission or exac in past 2 years but no ICS issued in last 3m # 
? Asthma 
Latest ACT 
? Asthma Latest ACT -20 at least 3 months ago 
? Asthma 3 71 - High Risk- not reviewed in the last 4 months 
? Asthma 3 72 - High Risk factors) - not reviewed in the last 4 months 
? Asthma 3 73 - High Risk factors) - not reviewed in the last 4 months
Report Name  Returns
? Asthma 3.0 Post Exacerbation Follow Up—————————————————————————————–
? Asthma 3.0 Exacerbation without follow-up review Patients who have had an exacerbation in the last year without a subsequent follow-up review
? Asthma 3.1 SABA Overuse—————————————————————————————–
? Asthma 3.11 >=12 SABA in last 12mAsthma patients (excluding COPD) receiving treatment that have been issued 12 SABAs in the last 12 months.
? Asthma 3.112 >=12 SABA in last 12m AND >=2 courses of steroidsAsthma patients (excluding COPD) receiving treatment that have been issued 12 SABAs AND equal to, or more than, 2 courses of steroids in the last 12 months.
? Asthma 3.113 >=12 SABA in last 12m AND <4 Preventers in last 12mAsthma patients (excluding COPD) receiving treatment that have been issued 12 SABAs AND less than 4 ICS in the last 12 months.
? Asthma 3.12 >=6 SABA in last 12mAsthma patients (excluding COPD) receiving treatment that have been issued 6 SABAs in the last 12 months.
? Asthma 3.121 >=6 SABA in last 12m AND >=2 courses of steroidsAsthma patients (excluding COPD) receiving treatment that have been issued 6 SABAs AND equal to, or more than, 2 courses of steroids in the last 12 months.
? Asthma 3.122 >=6 SABA in last 12m AND <4 Preventers in last 12mAsthma patients (excluding COPD) receiving treatment that have been issued 6 SABAs AND less than 4 ICS in the last 12 months.
? Asthma 3.2 LABA Safety—————————————————————————————–
? Asthma 3.2 LABA on repeat and no ICSAsthma patients with LABAs on repeat but no ICS.
 ? Asthma 3.3 More Severe Asthma Patients —————————————————————————————-
? Asthma 3.31 Likely Severe Asthma (high dose ICS, or LAMA or aminophylline or biologics)Asthma patients that are likely to have severe asthma as they one of the following medications on repeat; a high dose ICS, theophylline/ aminophylline, LAMA, respiratory immunotherapy.
? Asthma 3.311 Likely Severe Asthma (high dose ICS, or LAMA or aminophylline or biologics) – not under specialistAsthma patients with one of the following medications on repeat; a high dose ICS, theophylline/ aminophylline, LAMA, respiratory immunotherapy – ARE NOT under the care of a respiratory specialist or community team.
? Asthma 3.32 Likely Moderately Severe Asthma Asthma patients with possible high dose ICS on repeat.
? Asthma 3.4 >1 Exacerbation in last 12mPatients which have had at least 1 exacerbation in the last 12 months.
? Asthma 3.5 Possible Undertreatment—————————————————————————————–
? Asthma 3.51 Asthma QoF Register but no ICS issued in last 3mPatients on the Asthma QoF register that have not had an ICS issued in the last 3 months.
? Asthma 3.511 Asthma QoF Register but no ICS issued in last 3m (only if >1 SABA in 12m, with recent issue)Patients on the Asthma QoF register that have not had an ICS issued in the last 3 months. Have had at least one SABA issued in last 12 months AND a SABA issued in the last 4 months.
? Asthma 3.52 Admission or exac in past 2 years but no ICS issued in last 3m
? Asthma 3.6 Low ACT Score—————————————————————————————–
? Asthma 3.6 Latest ACT Score <20Patients whose asthma does not appear to be controlled.
? Asthma 3.61 Latest ACT <20 at least 4 months ago – Consider reviewPatients whose asthma did not appear to be controlled at least three months ago and who haven’t subsequently reported an improvement.  These patients could be followed up or asked to repeat the ACT test in person or online. 
? Asthma 3.7 Review Prioritisation—————————————————————————————–
? Asthma 3.71 Higher Risk – not reviewed in last 4 monthsAsthma patients with indicators of poor control who haven’t been reviewed in the last 4 months.
? Asthma 3.72 Higher Risk – (>=2 factors) – not reviewed in the last 4 monthsAs Above – increased level of risk.
? Asthma 3.73 Higher Risk – (>=3 factors) – not reviewed in the last 4 monthsAs Above -increased level of risk.
? Asthma 3.74 Higher Risk – (>=4 factors) – not reviewed in the last 4 monthsAs Above -increased level of risk.

Reports to help improve care of all Respiratory Diseases

The following reports below are located in the folder CDRC Quality > Respiratory

Machine generated alternative text:
? Concordance Alert All Ion actin inhalers # 
? Concordance Alert ICS AG (repeat not issued in the last 4m) # 
? Concordance Alert LABAAG (repeat not issued in the last 4m) # 
? Concordance Alert LAMA (selected drugs) (repeat not issued in the last 4m) #
Machine generated alternative text:
? ICS 
Safe 1 
? ICS safety 2 
- Child ossible hi h dose ICS without hei htin last 13m* 
TJ - Likely high dose ICS without Steroid card discussion in last 13m # 
Safety - High dose relvar in non-asthmatics
Machine generated alternative text:
? Inhalers 3M - Generic Prescribin Alen 
? Inhalers 31 - No Licensed Indication 
? Inhalers - Long Acting MDI without spacer in last 18m 
? Inhalers 34 - Exceeding Usual Quantity Long Acting Inhalers

These reports could be added to a batch reporting process so the relevant person or team in the practice is notified of the results at regular intervals for an ongoing quality improvement process – Automated Reporting


Template

Asthma Template

How to Access

In the lower left hand corner use the search bar, type in ‘Asthma CDRC’ and select the following template:

Alternatively, press F12 and search for ‘Asthma CDRC’, this will return the aforementioned template.

The Asthma CDRC Template can be used during consultations to provide an overview of current asthma issues, recording of key information, creating/ updating the patient’s personal action plan and more. Expand each node below to view information on each page of the Asthma CDRC template.

Asthma Template Main Page

The main Asthma page provides an overview of current asthma issues.  It is set out in three columns: a column to record important information or link to other templates; a column to show important information and warnings; a column to show expanded information from the record.  The asthma page should be completed after the core data template where smoking, weight etc., is covered.  The items in a red background are required for QoF.

  1. Current Symptoms

The Asthma Control Test (ACT) protocol takes you through the relevant questionnaire to calculate the ACT score. The child version of the ACT will be selected for children aged 11 and under. 

Once completed, click the Save Final Version button above the questionnaire. The ACT score and associated symptoms codes will be recorded automatically.  The ACT score will then show on the main template. 

If needed, the ACT score can be manually recorded (e.g. if the patient has completed a paper ACT questionnaire) in the boxes on the template 

The ACT questionnaire can be completed by the patient in SystmOnline ahead of the asthma review. 

Asthma Control Test - Adum older child 
4 
25 
During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, chest tightness, shortness of 
breath) wake you up at night or earlier than usual in the morning? 
04 or more times a week 
0 2-3 nights a week 
@ Once a week 
O Once or twice in the month 
O Not at all 
During the past 4 weeks, how often have you used your reliever inhaler (usually blue)? 
@ 3 or more times a day 
0 1-2 times a day 
0 2-3 times a week 
O Once a week or less 
O Not at all 
How would you rate your asthma control during the past 4 weeks? 
O Not controlled 
@ Poorly controlled 
O Somewhat controlled 
O Well controlled 
O Completely controlled 
ELL DONE - your asthma appears to have been under control over the last 4 weeks 
Read Codes Scores 
Scoring Group 
Asthma Control Test 
Score 
20-24 - ON TARGET 
Your asthma appears to have been REASONABLY WELL CONTROLLED during the past 4 weeks 
Less than 20 - Yours asthma may NOT HAVE BEEN CONTROLLED during the past 4 weeks

The Peak Flow templates allows recording and interpretation of peak flow readings.  A link to child PEFR tables will be shown for children. 

Peak Flow- Adults (1 5+) Peak Flow- Children (0-1 4) 
Peak Flow - Adults (15+) 
p EFR 
Best Ever peak Flow 
aest ever PEFR 
Predicted Peak Flow 
Peak Flow Calculator 
Predicted PEFR (EN 13826) 
2010 
03 May 2016 
U 16 Mar 2017 
03 Aug 2018 
03 Aug 2018 
Peak expiratory flow rate (XE2wr) 
Peak expiratory flow rate (XE2wr) 
Peak expiratory flow rate OXE2wr) 
Peak flow rate (XaEFM) 
Peak flow rate (XaEFM) 
Best ever peak expiratory flow rate 
375 Limin 
350 Limin 
250 Limin 
250 Limin 
346 Limin 
500 Limin 
2010 
DCS Peak Flow - predicted (latest) view has no data for patient 
Expand 
Expand 
Ihin
Peak Flow (L j min)

The number of exacerbations is also recorded here – this is a QoF requirement for annual review 

The following information is shown in the middle column 

  • Asthma status (i.e. never had asthma, suspected asthma, previous asthma, current asthma, on asthma QoF register) 
  • Latest asthma control test score and date 
  • Whether or not QoF requirement for annual review in the current year is completed, not achieved or excepted 
  • Latest PEFR 
  • Latest predicted PEFR 
  • Information about exacerbations 
    • Latest record of no’ of exacerbations in the last year 
    • Warnings showing for patients with 
      • 2 exacerbations in the last 12m 
      • Any exacerbation in the last 24m 
      • Any record of a severe exacerbation 
      • Any record of hospital asthma admission. 

The buttons in the third column will show more detailed information in the same categories 

OCS Asthma Exacerbations / Admissions (all) 
23 Apr 2010 
Nov 2016 
2g Dec 2016 
30 2017 
11 Jan 201g 
14 Aug 201g 
20 Aug 201g 
10 sep 201g 
18 sep 201g 
25 Nov 201g 
21 May 2020 
Exacerbation of asthma (Xal hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD) 
Exacerbation of asthma IXa1 hD)
  1. Steroid Safety 

The steroid safety section helps to promote safe use of oral and inhaled corticosteroids. 

The steroid safety button links to a steroid monitoring template which helps to give an overview of use of corticosteroids over time, along with safety and monitoring information (NB: template used across multiple clinical areas, not just Asthma): 

Home Initiation Gastroprotection 
Corticosteroids 
Monitoring Requirements 
Steroid Comparison 
28 Aug 2020 Standing systolic 
28 Aug 2020 Standing diastoli„ 
60 
Test 
Height for children 
Hbalc 
Steroid dose 
Oral steroids stopped 
Period 
t least annual 
t least annual 
nnual 
t least annual 
Height 
1 01 Aug 2017 
Haemoglobin Alc lev no nu 
Serum potassium No nu 
Last Recorded Steroid Dose 
No record of discussion about steroid card 
Current Gastroprotection 
Steroid Monitorina - CKS 
Core Data Entry 
Child Growth Chans 
Medication Timeline 
Last 3 Steroid Issues 
Prednisolone 
Prednisolone 
Prednisolone 
Take 
Take 
Five tm 
Corticosteroid use 
17 2020 
17 2020 
Ml Feb 2020 
Confirmnssue Steroid Treatment Card 
Consider Gastroprotection 
Record Steroid Information 
20 Oct 2020 
20 Oct 2020 
WHO FRAX 10 year osteoporotic fracture probability score (XaOgr) 
WHO FRAX 10 year hip fracture probability score [XaOgD) 
272% 
103% 
DCS Steroid Treatment Information view has no data for patient

There is a link to the child growth charts for children taking moderate or high dose ICS 

The middle column shows the following information: 

  • Oral steroid issues in the past 12 months 
  • A warning for patients appearing to be taking high dose ICS 
  • A warning to consider discussion about steroid safety cards for relevant patients 
  • A warning when appropriate monitoring is overdue for patients taking oral steroids 

The buttons in the third column show expanded information. 

  1. Asthma Triggers 

Current asthma triggers can be recorded here.  The middle column shows the latest recorded trigger and the button in the third colum shows all previous triggers. 

  1. Asthma Treatment 

Compliance with asthma treatment is recorded here 

The Asthma Rx Algorithm button links to an overview of up-to-date guidelines to help inform management.  The correct tab will be selected automatically based on the patients age. 

NICE under 5M 
NICE 5-16M NICE 
Newly in 
children and young people 
16 
Acute Exac 1 
index e 
th«agy al "%En'abqn 
Acute Ekac2 Occupation 
relkl 
a SABA 
Exercise Induced 
Action 
ICS Low dose (100-200mcg BOP) 
ressured Inhaler 
lenil 50 1-2P 
oprobec 50 1-2P bd±1-2 
lixotide evohaler 50 Ip bd 
var 50 Ipbd (from 
Ivesco 80 Ip od (from 
ry Powder Inhaler 
asyhaler Sudesonide 100 Ip bd±3 
ulmicorl 100 Ipbd OR 2P pm±4 
lixotide Accuhaler 50 Ip bd 
is in to 
ICS 
p—iGtric dose ICS pus LIRA 
t uromtrs;lbd in 4 ta B 
a LARA 
with a SABA 
ard LTRA 
a LARA 
within a "tAHT 
Inoderale dose GS a 
pie-diatrk; ICS 
a WART O' a a LARA a MART 
ICS Low Dose and LABA - can be used for MART) 
ressured Inhaler 
lutiform 50 Ip bd±7 
ry Powder Inhaler 
ymbicorl 100/6 Ip bd or 2P pm (from 6y)* 
eretide evohaler 50 Ip bd±g 
lutiform K-haler 50 Ip bd (from 12y) 
ICS Moderate Dose and LABA (300-400mcg BOP) e - can be used for MART) 
*hEn 
ressured Inhaler 
lutiform 50 2P bd±14 
eretide evohaler 50 2P bd±18 
lutiform K-haler 50 2P bd (from 12) 
Doses above are for children aged 5-1 ly 
ry Powder Inhaler 
eretide Accuhaler 100 Ip bd±18 
ymbicorl 100/6 2P bd (from 
ymbicorl 200/6 Ip bd (from 12y) or 2 puffs 
m* f14g 
For children 12-16} consider the severity of illness and body size when deciding 
whether to use paediatric or adult dose 
a LARA ag 
CS with a 
a SABA 
a SARA 
g;'uS a LARA a 
M&RT @mg-I

There is a link to the RightBreathe website which has extensive information about inhalers, spacers, pathways and really useful videos of inhaler techniques for all devices. 

Inhaler technique, demonstration of inhaler technique and spacer use can be recorded here. 

The middle column will show: 

  • Latest recorded compliance 
  • Current asthma medication (including any repeat oral steroids, azithromycin) 
  • A alert to show if the patient has rhinitis 
  • The following warnings: 
    • Patients receiving excessive SABA issues 
    • Patients with an exacerbation in the past 24m who are not receiving ICS 
    • Patients who appear to be overusing preventers 
    • Patients with an apparently unlicensed inhaler 
    • Patients with inappropriate generic repeats 
    • Patients who appear to have low concordance for non-ICS preventers 
  • Latest record of inhaler technique and demonstration 
  • Latest information about spacer use 
  • An alert to suggest spacer issue if the patient is on a preventer that is compatible with a spacer which has not been issued in the past 18 months. 

The buttons in the third column show more detailed information about medication issues 

OCS Inhalers (all groups - last 12m) 
Short Acting Bronchodilators 
Terbutaline 500micrograms/dose dry powder inhaler 
ONE INHALATION AS 
Terbutaline 500micrograms/dose dry powder inhaler 
ONE INHALATION AS 
Terbutaline 500micrograms/dose dry powder inhaler 
ONE INHALATION AS 
Terbutaline 500micrograms/dose dry powder inhaler 
ONE INHALATION AS 
Terbutaline 500micrograms/dose dry powder inhaler 
ONE INHALATION AS 
ICS only 
Flixotide 500micrograms/dose Accuhaler (GlaxoSmithKline inhale 1 dose twice daily 
Flixotide 500micrograms/dose Accuhaler (GlaxoSmithKline U inhale 1 dose twice daily 
ICS'LABA 
Sereflo 25micrograms/dose / 250micrograms/dose inhaler 
inhale 2 doses twice daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose 1 
dose daily 
Relvar Ellipta 184micrograms/dose / 22micrograms/dose dry n inhale 1 
dose daily 
LABA Alone 
LAMA Alone 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler 1 
dose daily 
Incruse Ellipta 55micrograms/dose dry powder inhaler (Glaxo ninhale 1 
dose daily 
LABAYLAMA 
ICS'LABAYLAMA 
Apse 
27 Nov 201g 
10 dan 2020 
07 Feb 2020 
16 Mar 2020 
01 dun 2020 
11 sep 2020 
10 Nov 2020 
27 Nov 201g 
07 Feb 2020 
16 Mar 2020 
14 Apr 2020 
28 May 2020 
07 Aug 2020 
sep 2020 
10 Nov 2020 
06 dan 2020 
07 Feb 2020 
16 Mar 2020 
14 Apr 2020 
28 May 2020 
07 Aug 2020 
sep 2020 
10 Nov 2020

The medication timeline function helps highlight medication concordance and what has been tried before: 

BUOESONIOE 
CETIRIZINE 
FLIXOTIOE 
FLUTICASONE 
CR SE 
MO TE UKAS 
SALB 
MOL 
SERETIOE 
TERBUT LINE 
TRANEXAMIC ACID
  1. Asthma Treatment Plan 

The Asthma Action Plan link goes to the asthma care planning tab of the template 

The middle column shows the most recent information about asthma management plans 

  1. Asthma Review 

The code for asthma review is recorded here.  Details of the main points of the conversation can be recorded as associated text.  

The middle column shows the latest asthma review code (and associated text). 

The button in the third column shows all previous asthma reviews. 

When closing the asthma template, users will be invited to code an asthma review if this hasn’t been done.   This is to help improve QoF performance. 

Exacerbation

The Exacerbation page of the Asthma CDRC template allows recording of key information required during assessment. 

Machine generated alternative text:
Asthma Exacerbation 
Asthma Exacerbation 
Action Plan Risk of exacerbation Diagnosis 
C) Asthma Exacerbation 
C) Asthma Severe Exacerbation 
o 
Life Threatining Exacerbation 
aoF Coding 
Exceptions aoF Rules Resources Reports RCP Questions 
Exacerbations 
Emergency admission, asthma 
Seen in accident and emergency department 
add 'asthma' as free text for A+E attendance 
p EFR 
Respiratory rate 
Temperature 
Oxygen saturation at perp 
Pulse rate 
Capillary refill time 
breat 
degC 
Secu 
23 Apr 2010 
2g Nov 2016 
Dec 2016 
30 Jan 2017 
011 201g 
14 Aug 201g 
20 Aug 201g 
10 sep 201g 
18 sep 201g 
25 Nov 201g 
21 May 2020 
Admissions 
23 Nov 2018 
Notes 
W 17 Aug 201g 
Exacerbation of asthma [Xal hD) 
Exacerbation of asthma [Xal hD) 
Exacerbation of asthma (Xal ho) 
Exacerbation of asthma (Xal hD) 
Exacerbation of asthma (Xal ho) 
Exacerbation of asthma [Xal hD) 
Exacerbation of asthma (Xal ho) 
Exacerbation of asthma (Xal hD) 
Exacerbation of asthma (Xal ho) 
Exacerbation of asthma [Xal hD) 
Exacerbation of asthma (Xal ho) 
Seen in accident and emergency department (gN1 g) 
uhnd 
Seen in accident and emergency department (gN1g) 
Breathing 
o 
Breathing easily (Xa042) 
C) Able to complete sentence in one breath (X 
o 
Unable to complete a sentence in one breat„ 
o 
Breathlessness causing difficuty eating (X 
Prednisolone 5mg Take 8 Nov 201g 
04 Mar 2020 
Seen in accident and emergency department (gN1g) 
Prednisolone 5mg Take 8 May 2020 
26 May 2020 Seen in accident and emergency department (gN1 g ) 
Other severe asthma information 
DNA 
Examination of respiratory system 
CKS Asthma GuidelinE Classifying Severty 
Treat patients with an exacerbation of asthma with steroids as soon as possible 
Consider quadrupling ICS for 14d AND 1 dose of prednisolone (dose as below) 
Ifthis is not suitable give course of steroids 
oChild < 2 years: 10 mg once a dayfor3 days 
oChild 2-5 years: 20 mg once a dayfor 3 days 
oChild 6-12 years: 30-40 mg once a dayfor 3 days 
oAdult or child 12 years: 40-50 mg once a dayfor 5 days 
Antibiotics should not be used unless the patient has fever AND purulent sputum 
or has signs of a bacterial infectiom 
25 Feb legs 
Notes 
08 Jul 2004 
05 Aug 2004 
1 Dec 2005 
13 May 200g 
4 Mar 2011 
13 Aug 2013 
22 Nov 2013 
Did not attend - no reason [XE2NM) 
Episode type = X' 
Did not attend - no reason OXE2NM) 
Did not attend - no reason [XE2NM) 
Did not attend asthma clinic (Xad2A) 
Did not attend - no reason [XE2NM) 
Did not attend - no reason [XE2NM) 
Did not attend (Xal kG) 
Did not attend (Xal kG)

There are links to the CKS page on the management of exacerbations and a quick reference page showing key features for classifying and managing acute asthma. 

Machine generated alternative text:
Acute Exacerbation in People Over 12y 
Moderate Asthma 
Increasing symptoms 
PEF -50-75% best or predicted 
No features of acute severe asthma 
Acute Severe Asthma Any one of: 
PEF 33-50% best or predicted 
Respiratory rate 225 
Hean rate 2110 
Inability to complete sentences in one breath 
Steroids and SABA 
Admit it no response to SABA 
Specialist fo//ow up for at least one year if admitted 
Life-threatening Asthma 
In a patient with severe asthma any one of: 
PEF best or predicted 
sp02 
Silent chest 
Cyanosis 
Poor respiratory effort 
Arrhythmia 
Exhaustion, altered conscious level 
Hypotension 
Admit, steroids, nebu/ised SABA with oxygen 
Specialist fo//ow up for at least one year 
Near Fatal Asthma 
Raised PaC02 and/or requiring mechanical 
ventilation with raised inflation pressures 
Need specialist fo//ow up indefinitey 
Acute Exacerbation in Children >2y 
Moderate Asthma 
Increasing symptoms 
PEF -50-75% best or predicted 
No features of acute severe asthma 
sueu 
Steroids (20mg pred 2-5% 3CL40mg -5'/ for 3 days) 
Acute Severe Asthma Any one of: 
PEF 33-50% best or predicted 
Cant complete sentences in one breath 
Too breathless to talk or feed 
Hean rate -125 (-5 years) 
-140 (2-5 years) 
Respiratory rate -30 (-5 years) 
-40 (2-5 years) 
Steroids and SABA ('.vRh oxygen if sats -94%) 
Admit 
Specialist fo//ow up is required if admitted (/oca/ recommendation) 
Life-threatening Asthma: Any one of: 
PEF -33% best or predicted 
sp02 
Silent chest 
Cyanosis 
Poor respiratory effort 
Exhaustion 
Hypotension 
Admit, steroids, nebu/ised SABA with oxygen 
Specialist fo//ow up is required (/oca/ recommendation)

The right hand column of the template shows information that might be helpful such as: previous exacerbations; previous hospital assessments and admissions; previous steroids; information about previous severe asthma; information about engagement 

Action Plan

The Action Plan page allows the viewing, creation and updating of a personal asthma plan. 

Asthma Action Plan 
Record Peak Flow 
Record Sest Ever Peak Flow 
Predicted Peak Flow Calculator 
PEFR 80/50/30% sand calculator 
Complete Adut Action Plan 
Complete Child Action Plan 
Complete Seat Action Plan 
Create Action Plan 
26 Jun 2021 Peak expiratory flow rate 
Best ever peak expiratory flow rate 
400 LJmin 
450 LJmin 
12 Jun 2020 
26 Jun 2021 
Predicted peak expiratory flow rate using EN 13826 limin 
Expected peak flow rate x 80% 
Expected peak flow rate x 50% 
Expected peak flow rate x 30% 
Asthma UK Child Asthma Action Plan 
320 limin 
200 limin 
120 limin 
12 Jun 2020 
12 dun 2020 
12 Jun 2020 
12 Jun 2020 06 28 
Entered by 
Finished by 
FORBES, Gareth (Dr) (General Medical Practitioner) 
FORBES, Gareth (Dr) (General Medical Practitioner) [12 Jun 2020 06:28] 
Expand 
Expand 
All Plans 
Everyday Asthma Care 
Preventer- Name 
Preventer- Colour 
Preventer Morning Dose (puffs) 
Preventer Evening Dose (puffs) 
Other daily medicines 
Reliever Inhaler- Name 
Reliever Colour 
Reliever Dose (puffs) 
When I Feel Worse 
Reliever Inhaler dose (puffs) 
Other things to do 
Pulmicorl 100 
White 
montelukast 
Salbutamol 
Blue 
panic 
Action Plan 
C) Agreed 
o 
Reviewed 
26 Jun 2021 
26 dun 2021 
9 
26 Jun 2021 
Asthma Action Plan to Mr Nic-Donotuse Mestpatientkamb 
Asthma self-management plan agreed 
Patient has a written asthma personal action plan 
Action Plan Declined

To Create An Asthma Care Plan 

If the relevant PEFR results have not already been recorded (they will be shown in the second column), use the buttons to record them.  The care plans can be based on either predicted or best ever PEFR. 

Click the PEFR 80/50/30% Band Calculator button.  Select predicted or best ever PEFR as the baseline at the next screen.  The 80/50/30% bands will be recorded and displayed in the second column.  (This step is not needed for the BEAT Asthma care plan). 

Click on the appropriate Complete ***** Action Plan button. The adult and child plans use the Asthma UK plans.  The BEAT plan is for children using the BEATAsthma care plan.  Complete the action plan questionnaire. NB clicking the buttons marked ‘A’ will display common presets to make data entry quicker.  Once the information is complete, click Save Final Version.  

1 - Everyday Asthma Care 
8 2 When Feel Worse 
3 - Asthma Attack 
Everyday Asthma Care 
Preventer Inhalers - Name, colour 
OVAR 50 (brown) 
Preventer Morning Dose (puffs) 
04 
Preventer Evening Dose (puffs) 
04 
Reliever Inhaler- Name, colour 
Salbutamol (blue) 
Reliever Dose (puffs) 
o 
04

If you wish to amend an existing plan, right click on the box in the second column showing the current plan and choose the Copy Questionnaire option, then choose Copy Comments.  An editable version of the previous questionnaire will then be displayed.  Amend any entries as appropriate, then click Save Final Version. 

Once the questionnaire is complete, click the Create Action Plan button to create a Word care plan, that can be saved and/or printed/emailed to the patient.  This button will prompt you to add the relevant QoF asthma plan code.  The latest care plan will be displayed in the bottom panel (the entry with the patient’s name) and can be emailed to the patient by right clicking on the entry and choosing Send via NHSMail 

26 Jun 2021 
26 dun 2021 
9 
26 Jun 2021 
Asthma Action Plan to Mr Nic 
Asthma self-management pl 
Patient has a written asthma 
Expon 
Send via NHSmaiI 
Print 
Attach to new Outlook message 
Link to Appointment

Use the final tickboxes on this tab to record that the patient has a care plan.  

Risk of Exacerbation

This page shows the key factors that increase the risk of asthma exacerbation and the relevant information from that patient’s record. 

10 Nov 2020 Number of asthma exacerbations in 0 
Asthma control test 
reatly 
ncreased 
oderately 
ncreased 
05 
lightly 
ncreased 
Children 
revious asthma attacks 
ersistent asthma symptoms 
uh-optimal drug regimen 
omorbid atopic disease 
ow-income family 
'tamin D deficiency 
ounger age 
obacco smoke exposure 
besity 
ow parental education 
Adults 
revious asthma attacks 
oor control 
nappropriate/excessive SABA 
Ider age 
emale 
educed lung function 
besity 
moking 
epresslon 
10 Nov 2020 
10 Nov 2020 Asthma treatment compliance unsatisfactory IXallY) 
CONSIDER LOW INHALER CONCORDANCE 
Sep 201g Body mass index observation (22K J 23111 Kg/ma 
Never smoked 
7 Oct 2005 
Percent predicted FEVI (XaEFz) 
NO clear record of severe asthma exacerbation 
DNA Information 
116% 
Additional Considerations For Severe Asthma Attacks 
Severe Asthma Attack (enter date) 
Non-attendance or poor engagement 
Safeguarding 
Expand 
Expand 
- 30 
Notes 
Did not attend - no reason [XE2NM) 
Episode type = X' 
NO record of current safeguarding concern
Diagnosis

This tab shows the key information required to diagnose asthma.  This includes: possible triggers, personal and FHx of atopy, allergy and anaphylaxis; spirometry; FeNO; PEFR variability; asthma challenge results. 

The top of the template has links to the NICE assessment algorithms. 

Asthma Exacerbation 
Diagnosis 
Asthma trigger(s) 
FHx Atopy 
Record Peak Flow 
Action Plan Risk of exacerbation 
O NICE Guidance 
Diagnosis aoF Coding Exceptions aoF Rules Resources Reports RCP Questions 
Alaorithm AAsthma Assessment Alaorithm B 5-1 Pathway Alaorithm C 1 7V+ Pathway 
20 Jul 201 5 Asthma trigger (Xalww) 
Notes 
hayfever 
HAS a record of atopy 
Asthma - On QoF register 
NO clear record of eczema 
14 Oct 
26 Jan legs 
10 Nov 2020 
01 May 2008 
07 Oct 2005 
FH Asthma (1 202) 
FH: Hay fever (1 204) 
Peak expiratory flow rate (XE2wr) 
380 Limin 
Predicted Peak Flow Calculator 
Spirometry• 
Forced expired ntric oxide 
Percentage of PEFR variabilty 
Asthma Challenge 
Predicted peak expiratory flow rate using EN 13826 limin 
FEVI/FVC percent (XaEFy) 
NO clear record of spirometry reversibility 
NO clear record of FeNO measurement 
NO clear record of PEFRvariability 
NO clear record of histamine or methacholine challenge 
015 sep 2014 
Eosinophil count- observation (42K ) 
NO clear record of RAST test 
go % 
03 1 ong/L 
—Expand 
Expand 
Expand 
Expand 
<--Expand 
—Expand 
—Expand 
—Expand 
Drug Allergies 
03 Mar 2014 
03 Mar 2014 
drug allergy (1 
non-drug allergy (1 )
Exceptions

The exceptions page allows recording and viewing of asthma exceptions 

Machine generated alternative text:
Asthma 
Exacerbation 
Action Plan 
Risk of exacerbation 
Diagnosis 
aoF Coding 
Exceptions 
aoF Rules 
Resources 
Reports 
RCP Questions 
General Asthma Exceptions 
Excepted: Informed dissent 
Excepted: Patient unsutable 
[3 Excepted: service unavailable 
General Asthma Exceptions 
Specific Asthma Exceptions 
Indicator Specific Exceptions 
Spirometry exception codes (AST002) 
Refuses asthma montoring (AST003) 
Refusal to give smoking status (AST004) 
AST002 The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures ofvariability or reversibility 
recorded between 3 months before or any time after diagnosis (45 - 80%) 15 Points 
When a child who was diagnosed with asthma before 8 years old becomes older than 8, OOF requires a code for some son of observation of reversible airway 
obstruction (once) or an exception (every year) to say that reversibility testing is not indicated/declined etc
QoF Coding

The QoF rules surrounding coding requirements for asthma diagnosis are complex and the business rules do not appear to reflect the QoF specification. 

Asthma Exacerbation Action Plan Risk of exacerbationDiagnosis OOF Coding Exceptions aoF Rules 
QoF Coding 
For patients with a diagnosis of asthma after 1/4/20 (including those who have recurred 
following a previous remission code), there must be: 
A specific spirometry code between 3m before and 6m after diagnosis AND 
PEFR code between 3m before and 6m after diagnosis 
FeNO code between 3m before and 6m after diagnosis 
If a patient registers with new asthma after 1/4/20 without the coding above, those codes 
must be added within 6 months of registratiom 
The easiest way to achieve this is to record a PEFR at the same time as the 
Resources Reports 
Asthma (833 ) 
Asthma 
RCP Questions 
QOF A <-Expand 
0 14 
21 sep 2000 
21 sep 2000 
05 Oct 2005 
13 Oct 2005 
20 Apr 2006 
26 Apr 2007 
lgAug 2008 
06 Mar 2012 
0 11 Jan 2013 
Exercise-induced asthma (173A)ß 
Exercise-induced asthma (173A)ß 
Asthma 
Asthma 
Asthma (833 ) 
Asthma 
Asthma 
Exacerbation of asthma (Xal hD) 
Asthma (833 ) 
spirometry with reversibility. 
Spirometry codes for Asthma 
PEFR codes 
DCS Asthma ASTSPIR Cluster view has no data for pati A 
QOF X 
AND 
OR 
14 Oct 
28 Oct 
26 Jan legs 
21 sep 2000 
21 sep 2000 
Peak expiratory flow rate ( 
Peak expiratory flow rate ( 
Peak expiratory flow rate ( 
Peak expiratory flow rate ( 
Peak expiratory flow rate ( 
360 um 
400 U 
3701-1 
A <-Expand 
FeN0 Codes 
Spirometry Exceptions Spirometry service not available 
Spirometry test declined 
Spirometry contraindicated 
Spirometry reversibilty testing contraindicated 
Spirometry not indicated 
Spirometry reversibilty testing not indicated 
Unable to perform spirometry
Asthma Resources

Links to important resources are shown on this tab.  Customised local information can be shown on this tab. 

Asthma Exacerbation 
Resources 
Action Plan 
Risk of exacerbation 
Diagnosis 
aoF Coding 
Exceptions 
aoF Rules 
Resources 
Reports 
RCP Questions 
Patient UK Asthma PIL 
Patient UK Peak Flow Meter PIL and diarv 
CKS Asthma Guideline 
Asthma Guidelines

Additional Resources

Opt-in Resources

The coding requirements for asthma are increasingly complex (and at times nonsensical).  The following resources will help keep on top of this.  As they are a little intrusive, these protocols need to be enabled at individual practices or CCGs. Contact contact-cdrc@ahsn-nenc.org.uk to enable them

Improve coding of asthma exacerbations 

This protocol will trigger for patients with asthma who are prescribed oral steroids if they have not had a code for exacerbation of asthma recorded during the same consultation. 

Machine generated alternative text:
Question 
You are prescribing steroids to this patient with asthma. 
Do you wish to record 'acute exacerbation of asthma'? 
This automatic alert is part of the CDRC Asthma Resources. 
You can disable it if is not wanted - Disabling Protocols 
The protocol is called Asmma/ COPD EncerDaüon Coding AUTO •

If the patient has COPD and asthma you will be offered the option of coding exacerbation of asthma or COPD or both. 

Whenever exacerbation of asthma is coded a prompt will be displayed to advice the user to arrange a follow up within a few days. 

Warning if a new diagnosis of asthma is recorded and the QoF business rules for recording spirometry, peak flow and FeNO have not been satisfied.  

Question 
This is a new diagnosis of asthma 
OOF Requirements 
Record 
Spirometry (or spirometry exception) 
AND 
FeNO OR Reversibilitywariability 
80th in the period 3m before to 6m after diagnosis 
*cord Relevant Test Resu!ts or Éxcept!ons

The following search will identify patients with a relevant new diagnosis without appropriate diagnostic tests.  You may wish to add this to an Automated Reporting process. 

CDRC Quality > Respiratory > ? Asthma QoF 1.0 – Diagnostic Tests Missing 

Footer

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter
  • Terms of Reference
  • Ethics & Governance
  • Privacy policy
  • Terms of use
  • Join CDRC Precision

Copyright © 2023 Clinical Digital Resource Collaborative